Merck (MRK) Cash from Financing Activities (2009 - 2026)

Merck (MRK) has reported Cash from Financing Activities for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 149.55% year-over-year to $1.8 billion in Q2 2026; TTM through Jun 2026 was $6.2 billion, a 141.84% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, up 72.67% from the prior year.
• Cash from Financing Activities was $1.8 billion for Q2 2026 at Merck, up from -$3.0 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $4.8 billion in Q4 2025 and troughed at -$5.8 billion in Q1 2025.
• A 5-year average of -$1.3 billion and a median of -$2.3 billion in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities soared 311.48% in 2023 and sank 392.43% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$1.6 billion in 2022, then plunged by 44.47% to -$2.2 billion in 2023, then slumped by 34.03% to -$3.0 billion in 2024, then jumped by 257.89% to $4.8 billion in 2025, then plunged by 62.91% to $1.8 billion in 2026.
• The last three Cash from Financing Activities figures came in at $1.8 billion (Q2 2026), -$3.0 billion (Q1 2026), and $4.8 billion (Q4 2025), per Business Quant data.